Ketoprofene Pharmy Ii

Ketoprofen, the active ingredient in Ketoprofene Pharmy Ii, is a non‑steroidal anti‑inflammatory drug presented as an injectable solution for intramuscular use. It is indicated for the relief of mild to moderate pain and for reducing inflammation in conditions such as rheumatoid arthritis, osteoarthritis and musculoskeletal injuries.\n\nGNH India supplies Ketoprofene Pharmy Ii as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels aligned to EU regulatory standards and provides technical support for safe handling through its global network.

Ketoprofen is an NSAID that reduces inflammation by inhibiting cyclooxygenase enzymes, and it is used for several musculoskeletal and rheumatic conditions.\n- Mild to moderate pain: provides analgesic relief by decreasing prostaglandin‑mediated nociception.\n- Rheumatoid arthritis: helps control inflammatory joint pain and swelling.\n- Osteoarthritis: reduces chronic joint discomfort and improves mobility.\n- Musculoskeletal injuries: alleviates pain and inflammation associated with sprains, strains and soft‑tissue trauma.

Ketoprofene Pharmy Ii may be associated with a range of adverse reactions, which are generally classified by frequency and severity.\n\nCommon Side Effects:\n- Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain.\n- Headache: mild to moderate intensity.\n- Dizziness or vertigo.\n- Injection site reactions: pain, erythema or swelling.\n- Mild fever.\n\nSerious or Rare Side Effects:\n- Severe gastrointestinal bleeding or ulceration.\n- Renal impairment: acute kidney injury or reduced function.\n- Hepatotoxicity: elevated liver enzymes or hepatitis.\n- Hypersensitivity reactions: anaphylaxis, Stevens‑Johnson syndrome or severe skin rash.\n- Cardiovascular events: increased risk of myocardial infarction.\n- Blood disorders: thrombocytopenia or anemia.

When using Ketoprofene Pharmy Ii, several precautions should be observed to minimise risk.\n- Assess renal function: avoid use in patients with severe kidney impairment.\n- Monitor hepatic status: use cautiously in those with liver disease.\n- Evaluate gastrointestinal risk: consider gastro‑protective agents for patients with ulcer history.\n- Check cardiovascular history: NSAIDs may increase risk of thrombotic events.\n- Review concomitant medications: avoid concurrent use with other NSAIDs or anticoagulants without supervision.\n- Store at ambient temperature: keep in original container, protect from moisture and light.

Ketoprofene Pharmy Ii can interact with other medicines, altering efficacy or safety.\n\nMajor Interactions (Avoid):\n- Anticoagulants (e.g., warfarin): increased bleeding risk.\n- Other NSAIDs or aspirin: heightened gastrointestinal toxicity.\n- Selective serotonin reuptake inhibitors (SSRIs): elevated bleeding potential.\n- ACE inhibitors or diuretics: may reduce renal perfusion.\n\nModerate Interactions (Monitor Closely):\n- Corticosteroids: additive risk of ulceration.\n- Lithium: possible increase in lithium levels.\n- Methotrexate: reduced clearance leading to toxicity.\n- Cyclosporine: enhanced nephrotoxic effect.